Innoviva Cash on Hand 2010-2024 | INVA
Innoviva cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Innoviva Annual Cash on Hand
(Millions of US $) |
| 2023 |
$194 |
| 2022 |
$291 |
| 2021 |
$202 |
| 2020 |
$246 |
| 2019 |
$351 |
| 2018 |
$115 |
| 2017 |
$129 |
| 2016 |
$150 |
| 2015 |
$187 |
| 2014 |
$240 |
| 2013 |
$465 |
| 2012 |
$248 |
| 2011 |
$241 |
| 2010 |
$310 |
| 2009 |
$155 |
Innoviva Quarterly Cash on Hand
(Millions of US $) |
| 2024-06-30 |
$217 |
| 2024-03-31 |
$178 |
| 2023-12-31 |
$194 |
| 2023-09-30 |
$180 |
| 2023-06-30 |
$173 |
| 2023-03-31 |
$144 |
| 2022-12-31 |
$291 |
| 2022-09-30 |
$301 |
| 2022-06-30 |
$284 |
| 2022-03-31 |
$217 |
| 2021-12-31 |
$202 |
| 2021-09-30 |
$135 |
| 2021-06-30 |
$43 |
| 2021-03-31 |
$283 |
| 2020-12-31 |
$246 |
| 2020-09-30 |
$479 |
| 2020-06-30 |
$417 |
| 2020-03-31 |
$384 |
| 2019-12-31 |
$351 |
| 2019-09-30 |
$297 |
| 2019-06-30 |
$250 |
| 2019-03-31 |
$192 |
| 2018-12-31 |
$115 |
| 2018-09-30 |
$55 |
| 2018-06-30 |
$108 |
| 2018-03-31 |
$56 |
| 2017-12-31 |
$129 |
| 2017-09-30 |
$168 |
| 2017-06-30 |
$136 |
| 2017-03-31 |
$170 |
| 2016-12-31 |
$150 |
| 2016-09-30 |
$149 |
| 2016-06-30 |
$154 |
| 2016-03-31 |
$168 |
| 2015-12-31 |
$187 |
| 2015-09-30 |
$206 |
| 2015-06-30 |
$229 |
| 2015-03-31 |
$251 |
| 2014-12-31 |
$240 |
| 2014-09-30 |
$269 |
| 2014-06-30 |
$349 |
| 2014-03-31 |
$371 |
| 2013-12-31 |
$465 |
| 2013-09-30 |
$506 |
| 2013-06-30 |
$443 |
| 2013-03-31 |
$459 |
| 2012-12-31 |
$248 |
| 2012-09-30 |
$273 |
| 2012-06-30 |
$295 |
| 2012-03-31 |
$200 |
| 2011-12-31 |
$241 |
| 2011-09-30 |
$265 |
| 2011-06-30 |
$284 |
| 2011-03-31 |
$294 |
| 2010-12-31 |
$310 |
| 2010-09-30 |
$192 |
| 2010-06-30 |
$211 |
| 2010-03-31 |
$225 |
| 2009-12-31 |
$155 |
| 2009-09-30 |
$154 |
| 2009-06-30 |
$176 |
| 2009-03-31 |
$179 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$1.205B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
